$ENSC
Ensysce Biosciences, Inc. Stock $ensc

$ensc Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224044768 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$3.419M
YoY Change		685.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$1.083M
YoY Change		-11.92%
% of Gross Profit
Research & Development		$1.691M
YoY Change		-11.71%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$2.774M
YoY Change		-11.73%
Operating Profit		$644.7K
YoY Change		-123.81%
Interest Expense		-$4.060K
YoY Change		-153.08%
% of Operating Profit		-0.63%
Other Income/Expense, Net		$17.02K
YoY Change		3.12%
Pretax Income		$661.8K
YoY Change		-124.6%
Income Tax
% Of Pretax Income
Net Earnings		$661.8K
YoY Change		-124.59%
Net Earnings / Revenue		19.36%
Basic Earnings Per Share		$0.07
Diluted Earnings Per Share		$0.07
COMMON SHARES
Basic Shares Outstanding	19.57M shares	8.471M shares
Diluted Shares Outstanding		9.890M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$4.154M
YoY Change		176.91%
Cash & Equivalents		$4.154M
Short-Term Investments
Other Short-Term Assets		$18.00K
YoY Change		125.0%
Inventory
Prepaid Expenses		$3.154M
Receivables		$1.783M
Other Receivables		$0.00
Total Short-Term Assets		$9.091M
YoY Change		229.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$294.2K
YoY Change		-36.16%
Total Long-Term Assets		$294.2K
YoY Change		-36.16%
TOTAL ASSETS
Total Short-Term Assets		$9.091M
Total Long-Term Assets		$294.2K
Total Assets		$9.385M
YoY Change		191.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.968M
YoY Change		114.7%
Accrued Expenses		$447.0K
YoY Change		-44.12%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$387.2K
YoY Change		-3.21%
Total Short-Term Liabilities		$2.802M
YoY Change		37.98%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$3.210K
YoY Change
Total Long-Term Liabilities		$3.213K
YoY Change		-89.46%
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.802M
Total Long-Term Liabilities		$3.213K
Total Liabilities		$2.805M
YoY Change		36.1%
SHAREHOLDERS EQUITY
Retained Earnings		-$126.0M
YoY Change		6.71%
Common Stock		$1.387K
YoY Change		383.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$6.908M
YoY Change
Total Liabilities & Shareholders Equity		$9.385M
YoY Change		191.57%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		$661.8K
YoY Change		-124.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$1.020M
YoY Change		-54.85%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.645M
YoY Change		-3414.08%
NET CHANGE
Cash From Operating Activities		-1.020M
Cash From Investing Activities
Cash From Financing Activities		3.645M
Net Change In Cash		2.625M
YoY Change		-210.77%
FREE CASH FLOW
Cash From Operating Activities		-$1.020M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1123604	usd
CY2023Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	97561	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1067703	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2288868	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	419217	usd
CY2023Q4	us-gaap	Assets Assets	2708085	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1936007	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	542260	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	854697	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3332964	usd
CY2023Q4	ENSC	Liability Classified Warrants Noncurrent LiabilityClassifiedWarrantsNoncurrent	26388	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	26388	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3359352	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	315	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121233901	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121557074	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-322858	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-328409	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-651267	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2708085	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	435380	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3906372	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3146157	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3146076	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1715488	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3416807	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5354713	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3643223	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3923277	usd
	us-gaap	Operating Expenses OperatingExpenses	9277990	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3153658	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7562502	usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	23175	usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	279873	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1279691	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12413	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23382	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1268929	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	440588	usd
	us-gaap	Profit Loss ProfitLoss	-4422587	usd
	us-gaap	Profit Loss ProfitLoss	-7121914	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12236	usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	12038	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4422803	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7121716	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-651267	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-651267	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001716947
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
CY2023Q3	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024Q3	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount		usd
CY2023Q3	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q3	ENSC	Stock Issued During Period Issuance Of Common Stock Upon Exercise Of Warrants StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	ENSC	Stock Issued During Period Issuance Of Common Stock Upon Exercise Of Warrants StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants		usd
	ENSC	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote		usd
	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	ENSC	Proceeds From Warrant Inducement Net Of Issuance Costs ProceedsFromWarrantInducementNetOfIssuanceCosts		usd
	ENSC	Transaction Costs From Public Offerings TransactionCostsFromPublicOfferings		usd
	ENSC	Transaction Cost Associated With Warrant Inducement TransactionCostAssociatedWithWarrantInducement		usd
	ENSC	Incremental Fair Value Of Warrant Inducement1 IncrementalFairValueOfWarrantInducement1		usd
	ENSC	Incremental Fair Value Of Warrant Inducement2 IncrementalFairValueOfWarrantInducement2		usd
	ENSC	Transaction Costs From Warrant Inducement And Public Offering Included In Accounts Payable TransactionCostsFromWarrantInducementAndPublicOfferingIncludedInAccountsPayable		usd
	ENSC	Settlement Of Commitment Fee In Shares SettlementOfCommitmentFeeInShares		usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
	ENSC	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38306
	dei	Entity Registrant Name EntityRegistrantName	Ensysce Biosciences, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2755287
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7946 Ivanhoe Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
	dei	Entity Address City Or Town EntityAddressCityOrTown	La Jolla
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92037
	dei	City Area Code CityAreaCode	(858)
	dei	Local Phone Number LocalPhoneNumber	263-4196
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	ENSC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19574014	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4153592	usd
CY2024Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	1782805	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3154110	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	9090507	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	294217	usd
CY2024Q3	us-gaap	Assets Assets	9384724	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1967573	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	447035	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	387176	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2801784	usd
CY2024Q3	ENSC	Liability Classified Warrants Noncurrent LiabilityClassifiedWarrantsNoncurrent	3213	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3213	usd
CY2024Q3	us-gaap	Liabilities Liabilities	2804997	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13870591	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13870510	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	1387	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	132886700	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-125979877	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	6908210	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-328483	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6579727	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9384724	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3418853	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1690674	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1914970	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1083433	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1227724	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	2774107	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3142694	usd
	us-gaap	Operating Expenses OperatingExpenses	7060030	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	644746	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2707314	usd
	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-146479	usd
CY2024Q3	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	6403	usd
CY2023Q3	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	17223	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4063	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7649	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	9146	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14683	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6934	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17023	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16508	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	661769	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-2690806	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1235	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-74	usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	290	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	661769	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2689571	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.32
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9890390	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9890390	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3085873	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3085873	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7782540	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7782540	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2145505	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2145505	shares
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3792807	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	55674	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-2690806	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1157675	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1479385	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1670001	usd
CY2024Q3	ENSC	Issuance Of Common Stock Value Upon Warrant Inducement Net Of Issuance Costs IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts	3385647	usd
CY2024Q3	ENSC	Transaction Costs Associated With Public Offering And Warrant Inducement TransactionCostsAssociatedWithPublicOfferingAndWarrantInducement	-637894	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20819	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	661769	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6579727	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4029652	usd
	ENSC	Stock Issued During Period Value Commitment Fee StockIssuedDuringPeriodValueCommitmentFee	400000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3056892	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9050004	usd
	ENSC	Transaction Costs Associated With Public Offering TransactionCostsAssociatedWithPublicOffering	-447879	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	250224	usd
	us-gaap	Profit Loss ProfitLoss	-7121914	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1157675	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1168600	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1670001	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1670001	usd
	ENSC	Stock Issued During Period Issuance Of Common Stock Upon Exercise Of Warrants StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfWarrants	2075219	usd
	ENSC	Issuance Of Common Stock Value Upon Warrant Inducement Net Of Issuance Costs IssuanceOfCommonStockValueUponWarrantInducementNetOfIssuanceCosts	8103943	usd
	ENSC	Transaction Costs Associated With Public Offering And Warrant Inducement TransactionCostsAssociatedWithPublicOfferingAndWarrantInducement	-1444756	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80574	usd
	us-gaap	Profit Loss ProfitLoss	-4422587	usd
	us-gaap	Profit Loss ProfitLoss	-4422587	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6579727	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6579727	usd
	us-gaap	Profit Loss ProfitLoss	-4422587	usd
	us-gaap	Profit Loss ProfitLoss	-7121914	usd
	ENSC	Accrued Interest And Interest Expense Related To Note Conversions AccruedInterestAndInterestExpenseRelatedToNoteConversions	33175	usd
	ENSC	Accrued Interest And Interest Expense Related To Note Conversions AccruedInterestAndInterestExpenseRelatedToNoteConversions	9146	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1197200	usd
	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants	23175	usd
	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants	279873	usd
	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-146479	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	80574	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	250224	usd
	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-135	usd
	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	1685244	usd
	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	-169083	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1729252	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1235252	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-57666	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2027375	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-131635	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1066036	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6738610	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8978107	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1670001	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	9050004	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2075219	usd
	ENSC	Proceeds From Warrant Inducement Net Of Issuance Costs ProceedsFromWarrantInducementNetOfIssuanceCosts	8103943	usd
	ENSC	Transaction Costs From Public Offerings TransactionCostsFromPublicOfferings	447879	usd
	ENSC	Transaction Cost Associated With Warrant Inducement TransactionCostAssociatedWithWarrantInducement	1319115	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	485190	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000208	usd
	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	276260	usd
	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	307131	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9768598	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7294786	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3029988	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1683321	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1123604	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3147702	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4153592	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1464381	usd
	ENSC	Incremental Fair Value Of Warrant Inducement1 IncrementalFairValueOfWarrantInducement1	10210616	usd
	ENSC	Incremental Fair Value Of Warrant Inducement2 IncrementalFairValueOfWarrantInducement2	5167372	usd
	ENSC	Conversions Of Convertible Notes Into Common Stock ConversionsOfConvertibleNotesIntoCommonStock	1168600	usd
	ENSC	Conversions Of Convertible Notes Into Common Stock ConversionsOfConvertibleNotesIntoCommonStock	3056892	usd
	ENSC	Proceeds From Financed Insurance Premiums Net ProceedsFromFinancedInsurancePremiumsNet	232155	usd
	ENSC	Proceeds From Financed Insurance Premiums Net ProceedsFromFinancedInsurancePremiumsNet	445737	usd
	ENSC	Transaction Costs From Warrant Inducement And Public Offering Included In Accounts Payable TransactionCostsFromWarrantInducementAndPublicOfferingIncludedInAccountsPayable	125641	usd
	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	290	usd
	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	12038	usd
	ENSC	Settlement Of Commitment Fee In Shares SettlementOfCommitmentFeeInShares	400000	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_803_eus-gaap--BasisOfAccounting_zXYuzWSm39r8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_825_z0yUsNC6eHa3">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2023, which may be found in the Company’s Form 10-K filed with the SEC on March 15, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zGx1ZWjeapyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zD1KDqpD9KYf">Use of estimates and assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zT5EomYtpuy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zV7vPQLy41Rf">Concentrations of credit risk and off-balance sheet risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had concentration in accounts payable, as one and <span id="xdx_901_eus-gaap--ConcentrationRiskBenchmarkDescription_c20240101__20240930_z4s1WGFNXiNf" title="Concentration of risk">two research and development vendors, respectively, made up greater than 10% individually, and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zWboqLbcbRk6" title="Concentration of risk">72</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zd3fXeAWJtkj" title="Concentration of risk">38</span>% in aggregate</span>, of the outstanding accounts payable balance as of September 30, 2024, and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Benchmark Description ConcentrationRiskBenchmarkDescription	two research and development vendors, respectively, made up greater than 10% individually, and 72% and 38% in aggregate
	us-gaap	Depreciation Depreciation	0	usd
CY2023	us-gaap	Depreciation Depreciation	0	usd
CY2024Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	3213	usd
CY2024Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	3213	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	26388	usd
CY2023Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	26388	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	10700000	usd
CY2024Q3	us-gaap	Grants Receivable GrantsReceivable	14000000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3418853	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	435380	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3906372	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1715488	usd
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19548590	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4737653	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13913074	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2902797	shares
CY2024Q3	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	2652845	usd
CY2023Q4	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	535474	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	378360	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	441871	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	104905	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	72358	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	18000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3154110	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1067703	usd
CY2024Q3	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	214251	usd
CY2023Q4	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	329228	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	95730	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	110202	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	137054	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	102830	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	447035	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	542260	usd
CY2024Q3	us-gaap	Contractual Obligation ContractualObligation	13300000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	38294	usd
CY2024Q3	us-gaap	Payments For Rent PaymentsForRent	8747	usd
	us-gaap	Payments For Rent PaymentsForRent	26242	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	8375	usd
	us-gaap	Payments For Rent PaymentsForRent	25124	usd
CY2024Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	380868	usd
CY2024Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	6308	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	387176	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2033249	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	18648	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1197200	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	854697	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4063	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7649	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1279691	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	9146	usd
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	745521	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1200000	usd
CY2024Q2	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	200000	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Legal Fees LegalFees	300000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	252123	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.5675
CY2023Q4	us-gaap	Share Price SharePrice	0.47
CY2023Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10200000	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10200000	usd
CY2024Q3	us-gaap	Legal Fees LegalFees	600000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	the Company issued to the placement agent as compensation unregistered warrants to purchase up to 752,969 shares of Common Stock
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	752969	shares
	ENSC	Shares Held In Abeyance SharesHeldInAbeyance	5703504	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.5675
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2024Q3	us-gaap	Share Price SharePrice	1.5675
CY2024Q3	us-gaap	Share Price SharePrice	0.47
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1101582	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	581314	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.15
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M25D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	581314	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.15
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M29D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	580414	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	32.48
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	581314	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	33.15
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y9M29D
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	39273	usd
	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Period Expected To Be Recognized SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized	P0Y9M29D
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	34007491	shares
CY2024Q3	ENSC	Warrant Or Right Exercisable WarrantOrRightExercisable	400000	shares

Files In Submission

Name	View Source	Status
0001493152-24-044768-index-headers.html	Edgar Link	pending
0001493152-24-044768-index.html	Edgar Link	pending
0001493152-24-044768.txt	Edgar Link	pending
0001493152-24-044768-xbrl.zip	Edgar Link	pending
ensc-20240930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
ensc-20240930_cal.xml	Edgar Link	unprocessable
ensc-20240930_def.xml	Edgar Link	unprocessable
ensc-20240930_lab.xml	Edgar Link	unprocessable
ensc-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENSC
Ensysce Biosciences, Inc. Stock $ensc

2024 Q4 Form 10-Q Financial Statement

#000149315224044768 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC Ensysce Biosciences, Inc. Stock $ensc

2024 Q4 Form 10-Q Financial Statement

#000149315224044768 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC
Ensysce Biosciences, Inc. Stock $ensc